186 related articles for article (PubMed ID: 30807397)
1. Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.
Srinivasan A; Scordino T; Baker A
J Pediatr Hematol Oncol; 2019 May; 41(4):334-335. PubMed ID: 30807397
[No Abstract] [Full Text] [Related]
2. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
3. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
[TBL] [Abstract][Full Text] [Related]
4. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
[No Abstract] [Full Text] [Related]
5. Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.
Srinivas U; Barwad A; Pubbaraju SV
Br J Haematol; 2014 Jun; 165(5):583. PubMed ID: 24456122
[No Abstract] [Full Text] [Related]
6. A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.
Chen D; Bachanova V; Ketterling RP; Begna KH; Hanson CA; Viswanatha DS
Am J Surg Pathol; 2013 Jan; 37(1):147-51. PubMed ID: 23232855
[TBL] [Abstract][Full Text] [Related]
7. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
Coltro G; Santi R
Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
[No Abstract] [Full Text] [Related]
8. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.
Jain N; Khoury JD; Pemmaraju N; Kollipara P; Kantarjian H; Verstovsek S
Blood; 2013 Nov; 122(19):3387-8. PubMed ID: 24203930
[No Abstract] [Full Text] [Related]
9. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S
Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910
[No Abstract] [Full Text] [Related]
10. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
11. Detection of FIP1L1-PDGFRA fusion by FISH.
Ma ES; Wong KF; Wong CL; Siu LL
Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
[No Abstract] [Full Text] [Related]
12. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
13. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
14. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
[TBL] [Abstract][Full Text] [Related]
15. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
[TBL] [Abstract][Full Text] [Related]
16. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
Pardanani A; Ketterling RP; Li CY; Patnaik MM; Wolanskyj AP; Elliott MA; Camoriano JK; Butterfield JH; Dewald GW; Tefferi A
Leuk Res; 2006 Aug; 30(8):965-70. PubMed ID: 16406016
[TBL] [Abstract][Full Text] [Related]
17. Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report.
Lv Y; Yao X; Ling Q; Suo S; Wang J; Zhao S; Gao X; Tong H; Jin J; Zhang X; Yu W
Ann Hematol; 2024 Jan; 103(1):357-360. PubMed ID: 37777636
[No Abstract] [Full Text] [Related]
18. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.
Shen Y; Shi X; Pan J
PLoS One; 2013; 8(8):e73059. PubMed ID: 24009732
[TBL] [Abstract][Full Text] [Related]
19. Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib.
Kim DS; Lee S; Choi CW
Korean J Intern Med; 2018 May; 33(3):642-644. PubMed ID: 28651427
[No Abstract] [Full Text] [Related]
20. A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement.
Hossain NM; Jain N; Steinmetz JL; McConville JF; Anastasi J; Odenike O
Chest; 2012 Dec; 142(6):1680-1683. PubMed ID: 23208343
[No Abstract] [Full Text] [Related]
[Next] [New Search]